Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
November, 2026
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Thomas Dayspring: Reshaping the Biology of Atherosclerotic Plaques with New Therapies
Thomas Dayspring/LinkedIn
Sep 25, 2026, 12:43

Thomas Dayspring: Reshaping the Biology of Atherosclerotic Plaques with New Therapies

Thomas Dayspring, Lipid Specialist, Educator at Early Medical, shared Atherosclerosis‘s post on LinkedIn, adding:

“A fantastic read worthy of a download – authors conclusion: ‘The future of atherothrombosis management lies in early detection, integrated targeting of multiple pathogenic pathways, and individualized patient care.'”

Atherosclerosis shared a post on LinkedIn about a recent article by L. Badimon et. al, adding:

“Could atherosclerosis become a chronic, controlled disease rather than a rupture-prone condition?

Intensive lipid lowering does more than reduce cardiovascular risk.

It can change plaque composition, promote stabilization, and in some cases induce regression.

At the same time, emerging anti-inflammatory therapies are beginning to address the residual risk that persists even after LDL cholesterol has been lowered.

The challenge now is identifying the right biological target for the right patient.

Could targeting lipids and inflammation together redefine the natural history of atherothrombosis?

Curious to explore how new therapies are reshaping the biology of atherosclerotic plaques?”

Title: A new era in atherothrombosis

Authors: L. Badimona, G. Vilahurb, G. Mendieta

Thomas Dayspring, Atherosclerosis

Stay updated with Hemostasis Today.

anti-inflammatory therapies Atherosclerosis Atherothrombosis cardiovascular risk G. Mendieta G. Vilahurb Health Hematology Hemostasis Hemostasis News Hemostasis Today L. Badimona LDL Cholesterol Medicine Thomas Dayspring thrombosis
NewsFeed